SGC-cGMP Signaling: Target for anticancer therapy

Advances in Experimental Medicine and Biology

Volumn 814, Issue , 2014, Pages 5-13

  Bian, Ka ^a   Murad, Ferid ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

cGMP dependent protein kinase (PKG); Cyclic guanosine monophosphate (cGMP); Natriuretic peptide; Nitric oxide synthase (NOS); Particulate guanylyl cyclase (pGC); Phosphodiesterase (PDE); Soluble guanylate cyclase (sGC)

Indexed keywords

8 BROMO CYCLIC AMP; BEVACIZUMAB; CYCLIC GMP; ENTINOSTAT; GUANYLATE CYCLASE; ISOBUTYLMETHYLXANTHINE; PANOBINOSTAT; TEMOZOLOMIDE; TRICHOSTATIN A; ZAPRINAST;

CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN; DRUG MECHANISM; GENE; GENE EXPRESSION REGULATION; GLIOMA; HUMAN; LUNG ADENOCARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SGC ALPHA1 GENE; SGC BETA1 GENE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CYCLIC GMP; GUANYLATE CYCLASE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84921687845     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1031-1_2     Document Type: Review

References (70)

1. Murad F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Biosci Rep. 1999;19:133-54.
2. Murad F. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA. 1996; 276:1189-92.
3. Murad F. What are the molecu lar mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle? Circulation. 1997;95:1101-3.
4. Bian K, Davis K, Kuret J, Binder L, Murad F. Nitrotyrosine formation with endotoxin-induced kidney injury detected by immunohistochemistry. Am J Physiol. 1999;277:F33-40.
5. Bian K, Gao Z, Weisbrodt N, Murad F. The nature of heme/iron-induced protein tyrosine nitration. Proc Natl Acad Sci U S A. 2003;100:5712-7.
6. Bian K, Murad F. Diversity of endotoxin-induced nitrotyrosine formation in macrophage-endotheliumrich organs. Free Radic Biol Med. 2001;31:421-9.
7. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 1991;351: 714-8.
8. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78:915-8.
9. Nathan C. Inducible nitric oxide synthase: regulation subserves function. Curr Top Microbiol Immunol. 1995;196:1-4.
10. Janssens SP, Shimouchi A, Quertermous T, Bloch DB, Bloch KD. Cloning and expression of a cDNA encoding human endothelium-derived relaxi ng factor/nitric oxide synthase. J Biol Chem. 1992;267:14519-22.
11. Marsden PA, Schappert KT, Chen HS, Flowers M, Sundell CL, Wilcox JN, et al. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett. 1992;307:287-93.
12. Sessa WC, Harrison JK, Barber CM, Zeng D, Durieux ME, D'Angelo DD, et al. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J Biol Chem. 1992;267:15274-6.
13. Bian K, Murad F. Nitric oxide (NO)-biogeneration, regulation, and relevance to human diseases. Front Biosci. 2003;8:d264-78.
14. Ducsay CA, Myers DA. eNOS activation and NO function: differential control of steroidogenesis by nitric oxide and its adaptation with hypoxia. J Endocrinol. 2011;210:259-69.
15. Saqueton CB, Miller RB, Porter VA, Milla CE, Cornfield DN. NO causes perinatal pulmonary vasodilation through K +-channel activation and intracellular Ca 2+ release. Am J Physiol. 1999;276:L925-32.
16. Pearce WJ, Longo LD. Developmental aspects of endothelial function. Semin Perinatol. 1991;15:40-8.
17. Ashman DF, Lipton R, Melicow MM, Price TD. Isolation of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate from rat urine. Biochem Biophys Res Commun. 1963;11:330-4.
18. Price TD,Ashman DF,Melicow MM. Organophosphates of urine, including adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate Biochim Biophys Acta. 1967 138 452-65
19. Bohme E, Munske K, Schultz G. Formation of cyclic guanosine-3',5'- monophosphate in various rat tissues. Naunyn Schmiedebergs Arch Pharmakol. 1969;264: 220-1.
20. Hardman JG, Sutherland EW. Guanyl cyclase, an enzyme catalyzing the formation of guanosine 3',5'-monophosphate from guanosine triphosphate. J Biol Chem. 1969;244:6363-70.
21. Schultz G, Bohme E, Munske K. Guanyl cyclase. Determination of enzyme activity. Life Sci. 1969;8: 1323-32.
22. White AA, Aurbach GD. Detection of guanyl cyclase in mammalian tissues. Biochim Biophys Acta. 1969; 191:686-97.
23. Goridis C, Morgan IG. Guanyl cy clase in rat brain subcellular fractions. FEBS Lett. 1973;34:71-3.
24. Kimura H, Murad F. Evidence for two different forms of guanylate cyclase in rat heart. J Biol Chem. 1974; 249:6910-6.
25. Beavo JA, Hardman JG, Sutherland EW. Hydrolysis of cyclic guanosine and adenosine 3',5'-monophosphates by rat and bovine tissues. J Biol Chem. 1970;245:5649-55.
26. Kakiuchi S, Yamazaki R, Teshima Y. Cyclic 3',5'-nucleotide phosphodiesterase, IV. Two enzymes with different properties from brain. Biochem Biophys Res Commun. 1971;42:968-74.
27. Cheung WY. Cyc lic 3', 5'-nucleotide phosphodiesterase. Effect of divalent cations. Biochim Biophys Acta. 1971;242:395-409.
28. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.
29. Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ Res. 1983;52:352-7.
30. Rapoport RM, Draznin MB, Murad F. Endotheliumdependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature. 1983;306:174-6.
31. Russwurm M, Behrends S, Harteneck C, Koesling D. Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Biochem J. 1998;335:125-30.
32. Nimmegeers S, Sips P, Buys E, Brouckaert P, Van de Voorde J. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vas cular smooth muscle relaxation. Cardiovasc Res. 2007;76:149-59.
33. Singh S, Lowe DG, Thorpe DS, Rodriguez H, Kuang WJ, Dangott LJ, et al. Membrane guanylate cyclase is a cell-surface rece ptor with homology to protein kinases. Nature. 1988;334:708-12.
34. Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H, et al. Selective activation of the B natriuretic p eptide receptor by C-type natriuretic peptide (CNP). Science. 1991;252:120-3.
35. Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci U S A. 1996;93:14827-32.
36. Biel M, Zong X, Hofmann F. Cyclic nucleotide-gated cation channels molecular diversity, structure, and cellular functions. Trends Cardiovasc Med. 1996;6: 274-80.
37. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7:328-38.
38. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therap eutic developments. Br J Pharmacol. 2012;165:1288-305.
39. Titani K,Sasagawa T,Ericsson LH,Kumar S,Smith SB,Krebs EG,et al. Amino acid sequence of the regulatory subunit of bov ine type I adenosine cyclic 3',5'-phosphate dependent protein kinase Biochemistry. 1984 23 4193-9
40. Martin E, Davis K, Bian K, Lee YC, Murad F. Cellular signaling with nitric oxide and cyclic guanosine monophosphate. Semin Perinatol. 2000;24:2-6.
41. Orstavik S, Natarajan V, Tasken K, Jahnsen T, Sandberg M. Characterization of the human gene encoding the type I alpha and type I beta cGMPdependent protein kinase (PRKG1). Genomics. 1997;42:311-8.
42. Ryan WL, Heidrick ML. Inhibition of cell growth in vitro by adenosine 3',5'-monophosphate. Science. 1968;162:1484-5.
43. Goldberg ND, Haddox MK, Nicol SE, Glass DB, Sanford CH, Kuehl Jr. FA, et al. Biologic regulation through opposing influences of cyclic GMP and cyclic AMP: the Yin Yang hypothesis. Adv Cyclic Nucleotide Res. 1975;5:307-30.
44. DeRubertis FR, Chayoth R, Field JB. The content and metabolism of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in adenocarcinoma of the human colon. J Clin Invest. 1976; 57:641-9.
45. Hadden JW, Hadden EM, Haddox MK, Goldberg ND. Guanosine 3':5'-cyclic monophosphate: a possible intracellular mediator of mitogenic influences in lymphocytes. Proc Natl Acad Sci U S A. 1972;69: 3024-7.
46. Takemoto DJ, Dunford C, Vaughn D, Kramer KJ, Smith A, Powell RG. Guanylate cyclase activity in human leukemic and normal lymphocytes. Enzyme inhibition and cytotoxicity of plant extracts. Enzyme. 1982;2 7:179-88.
47. Murad F, Kimura H, Hopkins HA, Looney WB, Kovacs CJ. Increased urinary excretion of cyclic guanosine monophosphate in rats bearing Morris hepatoma 3924A. Science. 1975;190:58-60.
48. Criss WE, Murad F. Urinary excretion of cyclic guanosine 3':5'-monophosphate and cyclic adenosine 3':5'-monophosphate in rats bearing transplantable liver and kidney tumors. Cancer Res. 1976;36: 1714-6.
49. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989; 83:1774-7.
50. Yang W, Ando J, Korenaga R, Toyo-oka T, Kamiya A. Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells. Biochem Biophys Res Commun. 1994;203:1160-7.
51. Garg UC, Devi L, Turndorf H, Goldfrank LR, Bansinath M. Effect of nitric oxide on mitogenesis and proliferation of cerebellar glial cells. Brain Res. 1992;592:208-12.
52. Murillo-Carretero M, Ruano MJ, Matarredona ER, Villalobo A, Estrada C. Antiproliferative effect of nitric oxide on epidermal growth factor-responsive human neuroblastoma cells. J Neurochem. 2002;83: 119-31.
53. Kumazoe M, Sugihara K, Tsukamoto S, Huang Y, Tsurudome Y, Suzuki T, et al. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest. 2013;123:787-99.
54. Frattola L, Carenzi A, Cerri C, Kumakura K, Trabucchi M. Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors. Acta Neurol Scand. 1976;54:382-90.
55. Zhu H, Li JT, Zheng F, Martin E, Kots AY, Krumenacker JS, et al. Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma. Mol Pharmaco l. 2011;80:1076-84.
56. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
57. Martin E, Sharina I, Kots A, Murad F. A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation. Proc Natl Acad Sci U S A. 2003;100:9 208-13.
58. Mathieu V, De Neve N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma or thotopic xenograft model. Neoplasia. 2008;10:1383-92.
59. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25:561-70.
60. Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TN M Classification for Lung Cancer. J Thorac Oncol. 2008;3:1213-23.
61. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725-31.
62. Layton DM. Understanding Kaplan-Meier and survival statistics. Int J Prosthodont. 2013;26:218-26.
63. Krumenacker JS, Katsuki S, Kots A, Murad F. Differential expression of genes involved in cGMPdependent nitric oxide signaling in murine embryonic stem (ES) cells and ES cell-derived cardiomyocytes. Nitric Oxide. 2006;14:1-11.
64. Mujoo K, Krumenacker JS, Wada Y, Murad F. Differential expression of nitric oxide signaling components in undif ferentiated and differentiated human embryonic stem cells. Stem Cells Dev. 2006;15: 779-87.
65. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, et al. Isolation of ca ncer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23:9392-400.
66. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
67. Cui X, Zhang J, Ma P, Myers DE, Goldberg IG, Sittler KJ, et al. cGMP-independent nitric oxide signaling and regulation of the cell cycle. BMC Genomics. 2005;6:151.
68. Pilz RB, Broderick KE. Role of cyclic GMP in gene regulation. Front Biosci. 2005;10:1239-68.
69. Gudi T, Lohmann SM, Pilz RB. Regulation of gene expression by cyclic GMP-dependent protein kinase requires nuclear translocation of the kinase: identifi-cation of a nuclear localization signal. Mol Cell Biol. 1997;17:5244-54.
70. Hickok JR, Vasudevan D, Antholine WE, Thomas DD. Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases. J Biol Chem. 2013;288:16004-15.